The state of Missouri currently has 352 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Saint Louis, Kansas City, St. Louis and Springfield.
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410
Recruiting
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC)
Register for Updates
Cryoablation vs Lumpectomy in T1 Breast Cancers
NCT05505643
Recruiting
This trial studies the efficacy and safety of cryoablation in patients with low risk, early stage breast cancer. Cryoablation is a method of killing a tumor by freezing it. The standard approach for patients with this kind of cancer is a lumpectomy. This study will review the safety of the cryoablation procedure initially, followed by comparing cryoablation to lumpectomy in order to see if the cryoablation results in better disease control, complication rates, and quality of life.
Gender:
Female
Ages:
50 years and above
Trial Updated:
04/04/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Breast Cancer, Breast Neoplasm
Register for Updates
Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer
NCT04289779
Recruiting
This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks (Day 1) plus cabozantinib 40 mg orally daily (Day 1 through Day 21). Patients will receive three cycles of treatment prior to cystectomy unless they discontinu... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Bladder Cancer
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri +27 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) Multi-Site RCT
NCT05442957
Recruiting
In this multi-center randomized clinical trial, head and neck cancer (HNC) survivors with clinically significant body image distress (BID) (N=180) will be randomized to BRIGHT (a brief video tele-cognitive behavioral therapy intervention) or Attention Control (AC, a manualized tele-supportive care intervention that controls for professional attention, dose, delivery method, and common factors). HNC survivors will complete IMAGE-HN (a validated patient-reported outcome measure [PROM] of HNC-relat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Head and Neck Cancer, Body Image Disturbance, Body Image, Survivorship, Psychosocial Impairment, Mental Health Issue
Register for Updates
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
NCT05511844
Recruiting
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Washington University, Saint Louis, Missouri
Conditions: HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
Register for Updates
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
NCT04968548
Recruiting
This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
03/28/2024
Locations: Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri +1 locations
Conditions: Lung Cancer
Register for Updates
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
NCT03118986
Recruiting
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact w... Read More
Gender:
All
Ages:
Between 30 months and 18 years
Trial Updated:
03/26/2024
Locations: The Children's Mercy Hospital, Kansas City, Missouri
Conditions: Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
Register for Updates
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
NCT03955978
Recruiting
Patients with inoperable endometrial cancer have limited treatment options. PD-L1 expression is common in endometrial cancers and RT induces tumor and systemic changes that induce the immune system. The purpose of this trial is to evaluate anti-PD-1/PD-L1 axis therapy in conjunction of standard of care RT for patients with inoperable endometrial cancer in order to establish the safety and efficacy of inducing an anti-tumor immune response.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Endometrial Cancer, Cancer of the Endometrium
Register for Updates
Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy
NCT05427214
Recruiting
This prospective imaging study is evaluating the feasibility of using the Halcyon 4.0 radiotherapy system for radiation therapy planning in patients with cancer. The Halcyon 4.0 system has been engineered to decrease the image acquisition time and the radiation exposure, but the system has not yet been clinically validated for use in radiation planning. This pilot study will evaluate images obtained on the Halcyon 4.0 system to assess if the quality is sufficient for radiation treatment plan con... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastric Cancer, Ovarian Cancer, Colon Cancer
Register for Updates
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
NCT06340646
Recruiting
The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimizati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Cholangiocarcinoma, Multiple Myeloma, Colon Cancer, Rectal Cancer
Register for Updates
Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
NCT03424850
Recruiting
The purpose of this research study is to learn more about the outcomes and early and late side effects of treating early stage prostate cancer with high dose rate brachytherapy.
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Prostate Cancer, Prostate Neoplasm
Register for Updates